Paratz Elizabeth D, Wilkinson Luke E, MacIsaac Andrew I
Department of Cardiology, St Vincent's Hospital Melbourne, Melbourne, Vic, Australia.
Department of Medical Engineering and Physics, St Vincent's Hospital Melbourne, Vic, Australia.
Heart Lung Circ. 2018 Jul;27(7):785-791. doi: 10.1016/j.hlc.2017.08.009. Epub 2017 Sep 18.
The risks of percutaneous coronary intervention (PCI) in obese and particularly morbidly obese patients remain uncertain.
1082 consecutive patients were categorised as non-obese (NO, body mass index (BMI) <30kg/m, n=688), obese (O, BMI 30-40kg/m, n=354) or morbidly obese (MO, BMI ≥40kg/m, n=40). Demographic and procedural information was collated. Monte Carlo simulations modelled radiation dosimetric data.
Obese and morbidly obese patients were younger (p=0.016), more frequently female (p=0.036), more frequently diabetic (p<0.0001), with better renal function (p<0.0001), and prior PCI (p=0.01). There was no difference in major adverse cardiovascular or cerebrovascular events (MACCE) (NO=1.2%, O=0.8%, MO=2.5%, p=NS), acute kidney injury, bleeding, length of stay, 30-day readmission or 30-day mortality. Obese and morbidly obese patients received increased contrast (NO=180 [150-230]mL, O=190 [160-250]mL, MO=200 [165-225]mL, p=0.016), dose area product (NO=75.56 [50.61-113.69]Gycm, O=116.4 [76.11-157.82]Gycm, MO=125.62 [92.22-158.81]Gycm, p<0.0001), entrance air kerma (NO=1439.42 [977.0-2075.5]mGy, O=2111.63 [1492.0-3011.0]mGy, MO=2376.0 [1700.0-3234.42]mGy, p<0.0001), and peak skin dose (NO=1439.42 [977.0-2075.5], O=2111.63 [1492.0-3011.0], MO=2376.0 [1700.0-3234.42], p<0.0001). Effective radiation dose increased in obese patients (NO=20.9±14.9mSv, O=27.4±17.1mSv, MO=24.1±12.6mSv, p<0.0001 for NO vs O, p=0.449 for NO vs MO).
Percutaneous coronary intervention can be performed in obese and morbidly obese patients without elevated risk for most clinical outcomes. However, radiation increases above levels that could cause both transient and late effects. Strategies should be pursued to minimise radiation dose.
肥胖尤其是病态肥胖患者经皮冠状动脉介入治疗(PCI)的风险仍不明确。
1082例连续患者被分为非肥胖(NO,体重指数(BMI)<30kg/m²,n = 688)、肥胖(O,BMI 30 - 40kg/m²,n = 354)或病态肥胖(MO,BMI≥40kg/m²,n = 40)。整理人口统计学和手术信息。蒙特卡洛模拟对辐射剂量学数据进行建模。
肥胖和病态肥胖患者更年轻(p = 0.016),女性比例更高(p = 0.036),糖尿病患病率更高(p<0.0001),肾功能更好(p<0.0001),且既往有PCI史(p = 0.01)。主要不良心血管或脑血管事件(MACCE)无差异(NO = 1.2%,O = 0.8%,MO = 2.5%,p = 无显著性差异),急性肾损伤、出血、住院时间、30天再入院率或30天死亡率也无差异。肥胖和病态肥胖患者接受的造影剂更多(NO = 180 [150 - 230]mL,O = 190 [160 - 250]mL,MO = 200 [165 - 225]mL,p = 0.016),剂量面积乘积更高(NO = 75.56 [50.61 - 113.69]Gy·cm²,O = 116.4 [76.11 - 157.82]Gy·cm²,MO = 125.62 [92.22 - 158.81]Gy·cm²,p<0.0001),入射空气比释动能更高(NO = 1439.42 [977.0 - 2075.5]mGy,O = 2111.63 [1492.0 - 3011.0]mGy,MO = 2376.0 [1700.0 - 3234.42]mGy,p<0.0001),以及皮肤峰值剂量更高(NO = 1439.42 [977.0 - 2075.5],O = 2111.63 [1492.0 - 3011.0],MO = 2376.0 [1700.0 - 3234.42],p<0.0001)。肥胖患者的有效辐射剂量增加(NO = 20.9±14.9mSv,O = 27.4±17.1mSv,MO = 24.1±12.6mSv,NO与O相比p<0.0001,NO与MO相比p = 0.449)。
肥胖和病态肥胖患者可以进行经皮冠状动脉介入治疗,大多数临床结局风险未升高。然而,辐射剂量高于可能导致短期和长期影响的水平。应采取策略尽量减少辐射剂量。